On Monday, August 24, Judy Bartlett-Roberto, Vice president of marketing for RefleXion Medical in Hayward will present an overview on the breakthrough cancer treatment technology her company is working on. Her previous experience includes serving as vice president for global marketing for the opthamology and optometry segments at Optovue, as a principal at JBR Consulting, and as vice president for marketing for the medical device company Cervel Neurotech.
RefleXion Medical is a Hayward company of more than 150 employees whose biology-guided radiotherapy allows it to detect and respond to signals emitted from the cancer itself and, for the first time, use them to guide immediate treatment. Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. RefleXion Medical’s breakthrough technology is challenging that and aims to one day treat multiple tumors, in parallel, during a single MRI session.
In 2018, RefleXion Medical raised more than $100 million in funding led by the global impact investment fund managed by TPG Growth. In 2019 the company received a $60 million senior secured term loan from Oxford Finance LLC to support the completion of the FDA clearance process for its biology-guided BgRT system and its subsequent commercial launch.
"The RefleXion system is the first and only one to have a patient’s tumors guide their own treatment and destruction,” said Samuel Mazin, founder and CTO of RefleXion. “Our goal is to eliminate disease throughout the body with solo treatments or in concert with immunotherapy and other advanced cancer drugs. We believe this could help reduce the more than 13 million global cancer deaths projected to occur in 2030 by the World Health Organization.”
RefleXion Medical is a Hayward company of more than 150 employees whose biology-guided radiotherapy allows it to detect and respond to signals emitted from the cancer itself and, for the first time, use them to guide immediate treatment. Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. RefleXion Medical’s breakthrough technology is challenging that and aims to one day treat multiple tumors, in parallel, during a single MRI session.
In 2018, RefleXion Medical raised more than $100 million in funding led by the global impact investment fund managed by TPG Growth. In 2019 the company received a $60 million senior secured term loan from Oxford Finance LLC to support the completion of the FDA clearance process for its biology-guided BgRT system and its subsequent commercial launch.
"The RefleXion system is the first and only one to have a patient’s tumors guide their own treatment and destruction,” said Samuel Mazin, founder and CTO of RefleXion. “Our goal is to eliminate disease throughout the body with solo treatments or in concert with immunotherapy and other advanced cancer drugs. We believe this could help reduce the more than 13 million global cancer deaths projected to occur in 2030 by the World Health Organization.”